Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07859202
Starting soon Phase 3

The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.

NCT07859202 · tracked via the Priya Life Science South Korea tracker
Sponsor
GL Pharm Tech Corporation
Phase
Phase 3
Started
2026-09
Last updated
2026-10-05

Condition(s) studied

Erectile Dysfunctions

Investigational drug(s) / intervention(s)

W2505W2505-P1W2505-RW2505-P2

W2505: PO, Once daily(QD), 12 weeks

W2505-P1: PO, Once daily(QD), 12 weeks

W2505-R: PO, Once daily(QD), 12 weeks

W2505-P2: PO, Once daily(QD), 12 weeks

Study summary

The purpose of this study is to evaluate the efficacy and safety of W2505.

Eligibility

Sex
MALE
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male aged 19 years or older. * Capable of completing study diaries and questionnaires independently. * Signed written informed consent. * run-in medication compliance ≥ 70% Exclusion Criteria: * Primary hypoactive sexual desire. * Erectile dysfunction caused by premature ejaculation or untreated endocrine disorders (e.g., untreated hypogonadism, hyperprolactinemia). * Other exclusions applied.

Primary outcome measure(s)

  • Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score — Baseline, Week 12
    Change from baseline in the erectile function domain score assessed using the International Index of Erectile Function (IIEF) questionnaire.

Trial sites (1)

FacilityCityRegionStatus
Inha University Hospital Incheon South Korea
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07859202 on ClinicalTrials.gov ↗ ← All trials in South Korea